Novo Nordisk Free Cash Flow 2012-2026 | NVO

Novo Nordisk annual/quarterly free cash flow history and growth rate from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
  • Novo Nordisk free cash flow for the quarter ending June 30, 2026 was 8,604.21, a year-over-year.
  • Novo Nordisk free cash flow for the twelve months ending June 30, 2026 was , a year-over-year.
  • Novo Nordisk annual free cash flow for 2025 was $8.927B, a 16.58% decline from 2024.
  • Novo Nordisk annual free cash flow for 2024 was $10.702B, a 11.31% decline from 2023.
  • Novo Nordisk annual free cash flow for 2023 was $12.066B, a 27.68% increase from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Novo Nordisk Annual Free Cash Flow
2025 8,926.85
2024 10,701.58
2023 12,066.41
2022 9,450.53
2021 7,742.60
2020 7,067.58
2019 5,674.31
2018 5,350.43
2017 5,096.40
2016 6,130.20
2015 4,922.01
2014 4,939.98
2013 4,049.10
2012 3,265.06
2011 3,433.54
Novo Nordisk Quarterly Free Cash Flow
2026-06-30 8,604.21
2026-03-31 2,000.25
2025-12-31 8,926.85
2025-09-30 10,926.30
2025-06-30 5,672.27
2025-03-31 1,575.95
2024-12-31 10,701.58
2024-09-30 11,438.98
2024-06-30 6,619.47
2024-03-31 850.30
2023-12-31 12,066.41
2023-09-30 12,111.87
2023-06-30 6,986.50
2023-03-31 3,619.94
2022-12-31 9,450.53
2022-09-30 8,740.52
2022-06-30 6,233.66
2022-03-31 3,327.55
2021-12-31 7,742.60
2021-09-30 8,521.74
2021-06-30 5,413.98
2021-03-31 1,597.17
2020-12-31 7,067.58
2020-09-30 7,453.58
2020-06-30 4,632.91
2020-03-31 1,232.56
2019-12-31 5,674.31
2019-09-30 5,154.51
2019-06-30 3,032.78
2019-03-31 1,102.84
2018-12-31 5,350.43
2018-09-30 4,732.73
2018-06-30 3,382.59
2018-03-31 1,279.20
2017-12-31 5,096.40
2017-09-30 4,746.32
2017-06-30 2,819.27
2017-03-31 1,504.84
2016-12-31 6,130.20
2016-09-30 4,890.30
2016-06-30 2,916.02
2016-03-31 944.19
2015-12-31 4,922.01
2015-09-30 3,748.37
2015-06-30 2,118.96
2015-03-31 506.65
2014-12-31 4,939.98
2014-09-30 3,899.98
2014-06-30 1,966.48
2014-03-31 620.17
2013-12-31 4,049.10
2013-09-30 3,214.92
2013-06-30 2,241.33
2013-03-31 1,113.61
2012-12-31 3,265.06
2012-09-30 3,090.85
2012-06-30 1,964.22
2012-03-31 1,128.14
2011-12-31 3,433.54
2011-09-30 2,958.68
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $193.067B $46.797B
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1085.319B 36.61
Johnson & Johnson (JNJ) United States $650.648B 24.86
AbbVie (ABBV) United States $466.363B 24.28
Merck (MRK) United States $362.354B 45.75
Roche Holding AG (RHHBY) Switzerland $344.965B 0.00
Novartis AG (NVS) Switzerland $267.847B 16.17
Pfizer (PFE) United States $157.653B 9.07
Sanofi (SNY) France $102.990B 8.67
Bayer (BAYRY) Germany $54.077B 9.62
Innoviva (INVA) United States $1.527B 5.22